newsfilter
← Latest News
Business Wire·

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

-- Collaboration Leverages Expertise Across Both Companies, Including Kite's Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing -- Kite, a Gilead Company (NASDAQ:GILD), and Arcellx, Inc.